Health Atlas
Menu
Evidence-led reference

Prevention & care

Refractive errors: myopia, hyperopia, astigmatism, presbyopia, correction, and myopia-control evidence

13 sources · Latest source check 2026-10-08 UTC
On this page

A refractive error means light is not focused correctly on the retina, making vision blurry. It is an optical problem, not one identical disease or a complete explanation for every visual symptom.[1]

Four common labels describe different focusing problems

Four common labels describe different focusing problems
TypeMain distinction
MyopiaDistant images are blurry; light focuses in front of the retina.[3]
HyperopiaLight focuses behind the retina; near vision may be difficult.[4]
AstigmatismCorneal or lens shape causes distorted or blurry vision at different distances.[5]
PresbyopiaAging reduces the lens’s ability to focus at near distance.[6]

Refraction describes how the eye bends light

The cornea and lens redirect light toward the retina. Eye length and the shape or flexibility of these optical structures affect the focal position. A refractive-error name describes this focusing relationship; it does not by itself describe retinal health, eye pressure or every reason that vision could be reduced.[2]

The categories can coexist

NEI explains that astigmatism often occurs alongside myopia or hyperopia, and that many people develop presbyopia in addition to another error. A person can therefore need different distance and near correction without one diagnosis replacing the other. The prescription and the health examination answer different questions.[2]

Myopia usually develops while the eye is growing

NEI describes onset commonly in childhood and progression into early adulthood. An eye that grows too long, or altered corneal or lens shape, focuses distant light in front of the retina. Family history matters, but an optical diagnosis cannot establish that one screen habit caused an individual case.[3]

High myopia is associated with other eye problems, including retinal detachment. Clear vision with glasses does not establish that those risks disappeared. Correcting focus and checking the retina are distinct purposes, even when the same appointment addresses both.[3]

Hyperopia is not simply the older-age reading-glasses problem

NEI describes hyperopia as often present from birth, although its symptoms may become apparent later. A shorter eye or optical-shape difference places the focal position behind the retina. Mild cases may produce few noticeable symptoms; an informal near-vision complaint cannot determine the underlying error.[4]

In children, substantial hyperopia can be associated with crossed eyes or amblyopia. The purpose of assessment may include visual development, not only whether the child complains about blur. Adult experience with reading glasses cannot supply a pediatric correction or observation plan.[4]

Astigmatism concerns shape, not a retina that is falling apart

The cornea or lens shape changes how light bends. Both nearby and distant objects can look distorted; symptoms can include eye strain or difficulty at night. Mild cases may go unnoticed. NEI states that its causes are not fully understood and does not describe a reliable prevention method.[5]

Presbyopia and hyperopia can produce similar complaints through different mechanisms

Presbyopia reflects a harder, less flexible aging lens. NEI distinguishes it from hyperopia even though both can make near tasks difficult. Moving a phone farther away can make print easier to see, but does not identify every cause of near-vision difficulty or restore the lens’s earlier flexibility.[6]

Larger print, suitable reading light and an appropriate near correction can improve function. Some people use reading glasses; others need a prescription addressing additional errors. A convenient pair of readers is not a substitute for investigating new or persistent visual problems.[6]

A focusing measurement and an eye-health examination have different purposes

NEI describes reading near and distant letters and checking for other problems during a comprehensive examination. Identifying an optical error does not exclude coexisting disease.[1]

An ordinary correction is not the same as a growth-control intervention

NEI’s January 2025 BLINK2 explanation distinguishes single-vision correction from specialized multifocal contacts intended also to slow eye growth. A child seeing clearly in their glasses is not, by that fact alone, evidence that myopia progression has stopped. Device design and intended outcome matter.[11]

A device authorization names a specific product and population

FDA’s September 2025 authorization for Essilor Stellest lenses covers correction and slowing progression in children aged 6–12 at treatment initiation. Its summary reports a two-year comparison measuring prescription change and axial eye length. These are not lifetime blindness outcomes, and the authorization cannot be generalized to every lens sold as “myopia control.”[9]

Outdoor time concerns prevention and progression, not a universal optical cure

WHO’s February 2026 explanation includes daylight outdoor time, breaks during near work and appropriate prescribed optical interventions in childhood myopia strategies. It distinguishes these from presbyopia, hyperopia and astigmatism, for which it does not describe prevention. A promising behavior for one outcome should not be advertised as reversing every prescription.[7]

Refractive surgery changes optical shape

FDA describes benefits and possible harms of laser refractive procedures. A corneal operation can reduce dependence on correction, but reading glasses or further correction may still be needed. Its purpose differs from preventing retinal disease or reversing every aspect of lens aging.[8]

Possible harms include glare, halos, reduced low-contrast vision, under- or overcorrection and dry-eye problems. Good chart acuity and satisfactory night vision are different outcomes. FDA also explains that monovision deliberately gives the eyes different focusing roles, with potential depth-perception or low-light tradeoffs. A guarantee of “20/20” cannot capture the whole benefit–harm question.[8]

Correctable blur can still create a substantial access problem

WHO describes affordability, geography, service quality and unequal access to spectacles as barriers. Education, work and independence can be affected despite an available optical correction. A useful health resource should explain those practical needs rather than treating every uncorrected prescription as a personal lifestyle failure.[7]

New flashes or a curtain-like shadow need a different response

NEI advises immediate eye or emergency assessment for suspected retinal detachment, including sudden new floaters, flashes or a dark curtain. Do not assume that such a change only needs stronger glasses.[13]

Evidence & uncertainty

Clearer vision and slowing childhood eye growth are different goals. Selected myopia-control devices have evidence and a defined US authorization, while a June 2026 combination-treatment trial was still a research announcement. Neither establishes one best method for every child, all refractive errors or lifelong complication prevention.[9][10]

Selected-source overview · Independent review pending

Published questions

Are myopia, hyperopia, astigmatism and presbyopia the same focusing disorder?

Selected-source overview · Independent review pending. Read the evidence context.

They describe different optical mechanisms and can coexist.[2]

Evidence behind this answer
  • Types of Refractive Errors

    agency condition or prevention explanation · 2025
    Selected relevant original official page passages inspected · September 2025: optical mechanisms and overlapping errors

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Is presbyopia just another name for farsightedness?

Selected-source overview · Independent review pending. Read the evidence context.

Lens aging and hyperopia are different mechanisms.[6]

Evidence behind this answer
  • Presbyopia

    agency condition or prevention explanation · 2024
    Selected relevant original official page passages inspected · December 2024: lens aging versus hyperopia, function and optical support

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Does correcting high myopia with glasses remove retinal-detachment risk?

Selected-source overview · Independent review pending. Read the evidence context.

Clearer focus does not establish removal of associated retinal risks.[3]

Evidence behind this answer
  • Nearsightedness (Myopia)

    agency condition or prevention explanation · 2024
    Selected relevant original official page passages inspected · December 2024: childhood course, optical shape and high-myopia risks

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Why can childhood hyperopia matter even without a complaint about blur?

Selected-source overview · Independent review pending. Read the evidence context.

Visual development, crossed eyes and amblyopia can be relevant.[4]

Evidence behind this answer
  • Farsightedness (Hyperopia)

    agency condition or prevention explanation · 2024
    Selected relevant original official page passages inspected · December 2024: focal position, symptoms and pediatric visual development

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Does clear distance vision in ordinary glasses show myopia progression has stopped?

Selected-source overview · Independent review pending. Read the evidence context.

Correction and slowing eye growth are different outcomes.[11]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Does the Stellest authorization cover every myopia-control lens and every age?

Selected-source overview · Independent review pending. Read the evidence context.

It names a particular device and treatment-start population.[9]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Did the June 2026 MTS2 announcement prove combined atropine and spectacle treatment works best?

Selected-source overview · Independent review pending. Read the evidence context.

It announces a comparison to be studied, not its results.[10]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Does laser correction guarantee comfortable vision in every lighting condition?

Selected-source overview · Independent review pending. Read the evidence context.

Chart acuity, glare, dryness and low-contrast function can differ.[8]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Stopping one contact-lens intervention was studied in older teens

The 2025 original BLINK2 report discusses two years of high-add multifocal lenses followed by a year of single-vision lenses. The reported increases after stopping were small and growth returned to age-expected rates using external benchmarks. This follow-up is not a newly randomized comparison of every stopping age, lens or childhood control method.[12]

A trial launch does not contain the trial’s results

NEI announced MTS2 in June 2026 to compare specialized spectacles, atropine drops and their combination in children aged 5 to under 12. It planned 24 months of treatment plus observation. NEI funding and manufacturer support for lenses were disclosed. The announcement cannot establish the combination’s outcome; full contemporary comparative appraisal remains incomplete.[10]

References

  1. Refractive Errors

    Agency condition or prevention explanation

    National Eye Institute · Content/publication date: 2025
    Accessed: 2026-10-08 UTC · Selected relevant original official page passages inspected
    Cited sections: December 2025: focusing definition and comprehensive examination

    Shared source with foundational eye page; combined attribution checked.

  2. Types of Refractive Errors

    Agency condition or prevention explanation

    National Eye Institute · Content/publication date: 2025
    Accessed: 2026-10-08 UTC · Selected relevant original official page passages inspected
    Cited sections: September 2025: optical mechanisms and overlapping errors

    Definition framework; not a comparative treatment review.

  3. Nearsightedness (Myopia)

    Agency condition or prevention explanation

    National Eye Institute · Content/publication date: 2024
    Accessed: 2026-10-08 UTC · Selected relevant original official page passages inspected
    Cited sections: December 2024: childhood course, optical shape and high-myopia risks

    Newer linked research distinguished from this page’s review date.

  4. Farsightedness (Hyperopia)

    Agency condition or prevention explanation

    National Eye Institute · Content/publication date: 2024
    Accessed: 2026-10-08 UTC · Selected relevant original official page passages inspected
    Cited sections: December 2024: focal position, symptoms and pediatric visual development

    No child’s correction or individual risk assigned.

  5. Astigmatism

    Agency condition or prevention explanation

    National Eye Institute · Content/publication date: 2024
    Accessed: 2026-10-08 UTC · Selected relevant original official page passages inspected
    Cited sections: December 2024: corneal/lens shape, symptoms and cause uncertainty

    Mild or absent symptoms do not select an individual treatment.

  6. Presbyopia

    Agency condition or prevention explanation

    National Eye Institute · Content/publication date: 2024
    Accessed: 2026-10-08 UTC · Selected relevant original official page passages inspected
    Cited sections: December 2024: lens aging versus hyperopia, function and optical support

    Newer presbyopia medicines are not comprehensively appraised here.

  7. Eye care, vision impairment and blindness: Refractive errors

    Agency condition or prevention explanation

    World Health Organization · Content/publication date: 2026
    Accessed: 2026-10-08 UTC · Selected relevant original official page passages inspected
    Cited sections: February 2026: myopia prevention/progression strategies and service-access barriers

    Public-health explanation; no personal outdoor-time or treatment protocol.

  8. What are the risks and how can I find the right doctor for me?

    Agency condition or prevention explanation

    US Food and Drug Administration · Content/publication date: not stated
    Accessed: 2026-10-08 UTC · Selected relevant original official page passages inspected
    Cited sections: Selected LASIK risk, correction and monovision passages

    Undated risk passages only; historical long-term-data wording not presented as a current evidence assessment.

  9. FDA Authorizes Marketing of First Eyeglass Lenses to Slow Progression of Pediatric Myopia

    Regulatory device authorization

    US Food and Drug Administration · Content/publication date: 2025
    Accessed: 2026-10-08 UTC · Selected relevant official page passages inspected
    Cited sections: September 2025: Stellest, ages 6–12 at initiation, two-year study endpoints and De Novo pathway

    Product-specific US authorization; not a universal device ranking.

  10. NEI launches clinical trial testing therapies that slow childhood myopia progression

    Agency trial announcement

    National Eye Institute · Content/publication date: 2026
    Accessed: 2026-10-08 UTC · Selected relevant official page passages inspected
    Cited sections: June 2026 MTS2 launch: intended comparison, population, follow-up and support

    Announcement, not completed-trial outcomes or independently verified current recruitment status.

  11. Contact lenses used to slow nearsightedness in youth have a lasting effect

    Agency research explanation

    National Eye Institute · Content/publication date: 2025
    Accessed: 2026-10-08 UTC · Selected relevant official page passages inspected
    Cited sections: January 2025: distinction between ordinary correction and multifocal growth-control purpose

    Agency account of BLINK/BLINK2; not an independent replication.

  12. Axial Growth and Myopia Progression After Discontinuing Soft Multifocal Contact Lens Wear

    Original trial follow up

    Berntsen DA and BLINK Study Group; JAMA Ophthalmology · Content/publication date: 2025
    Accessed: 2026-10-08 UTC · Original indexed abstract and selected original result passages inspected; no independent full-text appraisal
    Cited sections: January 2025 original discussion: BLINK2 stopping phase, small changes and external age benchmarks

    Selected original indexed discussion; complete methods, funding and limitations not independently appraised.

  13. Retinal Detachment

    Agency condition or prevention explanation

    National Eye Institute · Content/publication date: 2025
    Accessed: 2026-10-08 UTC · Selected relevant original official page passages inspected
    Cited sections: November 2025: new floaters/flashes/curtain and immediate assessment

    Urgent changes should not be assumed to need only new glasses.

Scope & review

Population
Optical-error literacy across ages; pediatric visual development and device-specific myopia-control settings distinguished
Exposure or intervention
Refraction, correction, growth-control purposes, lifestyle role, device authorization and surgery risks
Comparison
Source-specific symptom, care, screening or comparator settings
Outcomes
Visual clarity, function, eye growth, prescription change, adverse effects and access
Timeframe
Development and aging; dated 2024–2026 explanations and selected follow-up/authorization/announcement
Jurisdiction
Selected US/UK agency and professional guidance; jurisdiction and eligibility differences are labeled

Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.

Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.

Revision history
  • 2026-10-08 UTC: Added a sourced explanation in a bounded ten-article batch; qualified review remains pending.

What this article still leaves open

  • Independent eye-care review, complete contemporary myopia-control comparisons, prescription terminology, presbyopia medicines and long-term surgery outcomes remain incomplete.
  • No prescription strength, child’s progression, outdoor-time target, device, eye drop or operation is selected for an individual.
Suggest a correction

Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.

Explore the topic map

Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.